Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Why Does Immunotherapy Cost So Much?

Immunotherapy – reprogramming the immune system to attack cancer cells – is a rapidly growing and promising field in cancer research and treatment.

Read More »

PTC’s SMA drug shows promise in two studies

PTC Therapeutics announced interim data from part 1 of the company’s open-label clinical trials of risdiplam (RG7916) for Type 1, 2 and 3 spinal muscular atrophy (SMA).

Read More »

Gilead to launch generic hepatitis drugs

Gilead Sciences Inc. plans to launch generic versions of the company’s hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Read More »

U.S. regulator approves Teva migraine drug, shares rise

Shares of Israeli drugmaker Teva Pharmaceutical Industries rose more than 5 percent after the U.S. Food and Drug Administration approved the company’s new migraine treatment.

Read More »

Novartis wins EU approval for blood cancer therapy Kymriah

Novartis received European approval for Kymriah, the Swiss drugmaker’s gene-modifying therapy for blood cancer.

Read More »

U.S. health secretary says agency has power to eliminate drug rebates

U.S. Health and Human Services Secretary Alex Azar said it was within his agency’s power to eliminate rebates on prescription drug purchases, a key element of the Trump administration’s plan to lower prescription medicine costs.

Read More »

Amicus receives U.S. approval for Fabry disease drug

U.S. health regulators approved Amicus Therapeutics’ Galafold as the first oral therapy to treat Fabry disease, a rare and sometimes fatal condition.

Read More »

Republican pricing projects could hit industry bottom line

Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.

Read More »

Trump says will make announcement on reducing drug prices

U.S. President Donald Trump said his administration would make an announcement on reducing drug prices, but he did not offer specifics.

Read More »

Novartis Halts Planned Price Increases For Drugs Amid Scrutiny of Relationship With Trump Attorney

Novartis is halting planned price increases on the Swiss pharma giant’s medications after President Donald Trump took Pfizer to task over price hikes, with Pfizer subsequently agreeing to roll back the company’s price increases.

Read More »

Trump told Pfizer CEO price hikes hurt his drug plan: source

U.S. President Donald Trump called Pfizer Chief Executive Ian Read to say the company’s July 1 price hikes had complicated the administration’s drug pricing plans, prompting the company to defer its planned increases, according to a source familiar with the matter.

Read More »

Trump slams Pfizer, other companies after July 1 drug price hikes

U.S. President Donald Trump took aim at Pfizer Inc. and other U.S. drugmakers after they raised prices on some of their medicines on July 1, 2018, saying his administration would act in response.

Read More »

Mixed FDA results for Achaogen infection drug Zemdri

The U.S. FDA cleared Achaogen’s antibiotic to treat adults with complicated urinary tract infections, but the drug failed to win approval for treating bloodstream infections.

Read More »

Payer Access Special Feature: Straining the system

Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.

Read More »

U.S. drug prices hit by insurer tactic against copay assistance: analysis

A recently adopted tactic by U.S. health plans to limit the financial assistance drugmakers provide directly to consumers for prescription medicines is taking a toll on drug prices, according to a new analysis.

Read More »

Novartis wins key European panel’s thumbs-up for migraine drug

Novartis’ new migraine drug Aimovig won a key recommendation from a key European panel on Friday, helping open the way for potential sales before the end of the year for a medicine the Swiss drugmaker is counting on to boost growth.

Read More »

Trump to deliver speech on drug prices: White House

U.S. President Donald Trump will deliver a speech about lowering prescription drug prices, a White House spokesman said.

Read More »

President Trump wants to go further on drug prices: HHS Secretary

Health and Human Services Secretary Alex Azar said President Donald Trump wants to go further in lowering drug prices, an issue he campaigned on during the 2016 presidential race.

Read More »

FDA’s Gottlieb blames industry ‘Kabuki drug pricing’ for high costs

U.S. Food and Drug Administration chief Scott Gottlieb criticized pharmacy benefit managers, health insurers and drugmakers for “Kabuki drug-pricing constructs” that profit the industry at the expense of consumers.

Read More »

Aclaris’ drug to treat skin growth gets FDA nod

Aclaris Therapeutics Inc.’s drug to treat a common type of skin growth called seborrheic keratoses received FDA clearance.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom